Polymyositis

Introduction

Polymyositis is a rare inflammatory myopathy characterized by chronic muscle inflammation and progressive weakness. It primarily affects the proximal muscles, leading to difficulty in activities such as climbing stairs or lifting objects. Understanding its clinical features, pathogenesis, and management is crucial for early diagnosis and effective treatment.

Definition and Classification

Definition of Polymyositis

Polymyositis is an idiopathic inflammatory disorder of skeletal muscles, causing symmetrical, proximal muscle weakness and elevated muscle enzymes. The disease is autoimmune in nature and is part of the broader group of idiopathic inflammatory myopathies.

Idiopathic Inflammatory Myopathies

Polymyositis belongs to the family of idiopathic inflammatory myopathies, which also includes dermatomyositis, inclusion body myositis, and necrotizing autoimmune myopathy. These conditions share common features of muscle inflammation but differ in clinical presentation, histopathology, and prognosis.

Differentiation from Dermatomyositis and Inclusion Body Myositis

• Dermatomyositis: Associated with characteristic skin manifestations such as heliotrope rash and Gottron’s papules, in addition to muscle weakness.
• Inclusion Body Myositis: Typically affects older adults, often causing distal muscle weakness, and has a slower, progressive course with poor response to immunosuppressive therapy.

Epidemiology

• Incidence and prevalence: Polymyositis is a rare disorder, with an estimated incidence of 1–10 cases per million population per year.
• Age and sex distribution: The condition most commonly affects adults between 30 and 60 years of age and shows a higher prevalence in females compared to males.
• Geographical variations: There is no significant geographical predilection, although some studies suggest slightly higher rates in certain regions due to genetic and environmental factors.

Etiology and Pathogenesis

• Genetic predisposition: Certain human leukocyte antigen (HLA) subtypes have been associated with increased susceptibility to polymyositis.
• Autoimmune mechanisms: Polymyositis is mediated by T-cell infiltration into muscle fibers, leading to muscle fiber necrosis and inflammation.
• Environmental triggers: Viral infections, medications, or toxins may initiate or exacerbate the autoimmune response in genetically predisposed individuals.
• Immunopathology and muscle fiber damage: Cytotoxic CD8+ T cells attack muscle fibers expressing major histocompatibility complex (MHC) class I antigens, causing progressive muscle weakness and damage.

Clinical Features

Muscular Symptoms

• Proximal muscle weakness: Symmetrical weakness of the shoulder, hip, and neck muscles is the hallmark feature, making tasks like climbing stairs, rising from a chair, or lifting objects difficult.
• Fatigue and exercise intolerance: Patients often experience rapid fatigue and reduced endurance during physical activity.
• Myalgia: Muscle pain and tenderness may be present, though not always prominent.

Systemic Manifestations

• Fever and malaise: Low-grade fever and general feelings of unwellness may accompany muscle symptoms.
• Arthralgia and arthritis: Mild joint pain or inflammation can be observed in some patients.
• Interstitial lung disease: Pulmonary involvement may occur, presenting with cough, dyspnea, or reduced lung function.
• Cardiac involvement: Rarely, myocarditis or arrhythmias may develop in severe cases.

Complications

• Muscle atrophy: Chronic inflammation can lead to irreversible muscle wasting if untreated.
• Respiratory failure: Weakness of respiratory muscles may cause difficulty breathing in advanced disease.
• Secondary infections: Immobility and immunosuppressive therapy increase the risk of infections.

Laboratory Investigations

• Serum muscle enzymes: Creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), and transaminases are typically elevated, reflecting muscle damage.
• Autoantibodies: Myositis-specific antibodies, such as anti-Jo-1, anti-Mi-2, and anti-SRP, can aid in diagnosis and classification.
• Inflammatory markers: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) may be mildly elevated, indicating systemic inflammation.

Electrophysiology and Imaging

• Electromyography (EMG): EMG studies typically show short-duration, low-amplitude motor unit potentials with fibrillation and positive sharp waves, indicating muscle inflammation and damage.
• Magnetic Resonance Imaging (MRI): MRI can detect areas of muscle edema, inflammation, and fatty replacement, helping to guide biopsy sites and monitor disease activity.
• Ultrasound in myositis: High-resolution ultrasound may reveal muscle enlargement, increased echogenicity, and hypervascularity, supporting the diagnosis and assessment of disease progression.

Histopathology

• Muscle biopsy findings: Biopsy typically shows endomysial inflammation, fiber necrosis, and regeneration, which are characteristic of polymyositis.
• Inflammatory cell infiltrates: Predominantly CD8+ T lymphocytes surround and invade non-necrotic muscle fibers expressing MHC class I antigens.
• Necrosis and regeneration patterns: Muscle fibers exhibit patchy necrosis with varying degrees of regeneration, reflecting ongoing immune-mediated damage and repair.

Diagnosis

• Clinical diagnostic criteria: Diagnosis is based on symmetrical proximal muscle weakness, elevated muscle enzymes, characteristic EMG changes, and compatible biopsy findings.
• Differential diagnosis: Includes dermatomyositis, inclusion body myositis, muscular dystrophies, drug-induced myopathies, and metabolic or endocrine myopathies.
• Role of biopsy, labs, and imaging: Muscle biopsy remains the gold standard, while laboratory tests and imaging provide supportive evidence and help monitor disease activity.

Treatment and Management

Pharmacological Therapy

• Glucocorticoids: Prednisone is the first-line treatment to reduce inflammation and improve muscle strength.
• Immunosuppressive agents: Methotrexate, azathioprine, and mycophenolate mofetil are used as steroid-sparing agents or in refractory cases.
• Biologics and newer therapies: Rituximab and intravenous immunoglobulin (IVIG) may be considered for patients not responding to conventional therapy.

Non-Pharmacological Therapy

• Physical therapy and rehabilitation: Tailored exercise programs maintain muscle strength, prevent contractures, and improve functional outcomes.
• Occupational therapy: Assists patients with activities of daily living and recommends adaptive devices to enhance independence.

Management of Complications

• Respiratory support: Patients with severe respiratory muscle weakness may require ventilatory assistance or non-invasive ventilation.
• Cardiac monitoring: Regular assessment for arrhythmias, myocarditis, or heart failure is important due to potential cardiac involvement.
• Prevention of infections: Immunosuppressive therapy increases infection risk, so vaccinations, hygiene measures, and prompt treatment of infections are essential.

Prognosis

• Factors affecting outcome: Early diagnosis, timely initiation of therapy, extent of muscle involvement, and presence of extramuscular manifestations influence prognosis.
• Long-term functional status: Most patients respond to therapy and regain significant muscle strength, although some may have persistent weakness or disability.
• Mortality and morbidity: Mortality is generally low but may increase with severe systemic involvement, including interstitial lung disease or cardiac complications.

References

1. Dalakas MC. Inflammatory Muscle Diseases. N Engl J Med. 2015;372(18):1734-1747.
2. Hengstman GJ, Vree Egberts WT, van Engelen BG, et al. Polymyositis: pathogenesis, clinical features, and management. Curr Opin Neurol. 2006;19(5):485-491.
3. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325(21):1487-1498.
4. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of polymyositis and related inflammatory myopathies. Curr Opin Rheumatol. 2010;22(6):619-625.
5. Oddis CV, Aggarwal R, Reed AM. Approach to the adult with inflammatory myopathy. Lancet. 2011;378(9792):1254-1264.
6. Love LA, Leff RL, Fraser DD, et al. Polymyositis: clinical features, diagnostic criteria, and therapy. Ann Intern Med. 1991;115(8):588-596.
7. Rose MR, Oelke K, Oddis CV. Management of idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2003;15(6):734-742.
8. Vleugels RA, Miller FW. Management of polymyositis and dermatomyositis. Curr Opin Rheumatol. 2009;21(6):609-615.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(7):403-407.
10. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971-982.